$heff's $tation of $tocks & $olid DD

[$heff]

APPA..$.52..PDUFA play for March 27th with strong insider ownership & what looks to be plenty of upside. This stock has strong insider ownership as well as strong insider buying. It is held by Baker Brothers (10% owner), Kevin Tang (10% owner), & others who are key figures in the biotech space for stocks.

Dec 14th Jeffries initiates AP Pharma as a Buy and $1.50 target price.
http://bit.ly/R4sNBe

June 13th JMP Securities Starts AP Pharma (APPA) at Market Outperform..http://bit.ly/12ziLdO

Large Insider Buy on July 25th by SPCH (Standard Pacific Capital Holdings), LLLP of 38m shares at $.525
http://www.sec.gov/Archives/edgar/data/818033/000142681212000002/xslF345X03/primary_doc.xml
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8485790

TANG Capital Management acquired 9.5m shares at $.525 on July 25th. Holding almost 70M shares.
http://www.sec.gov/Archives/edgar/data/818033/000120919112039419/xslF345X03/doc4.xml

Analysts Rankings on APPA (JMP Securities & Wedbush)
http://bit.ly/U7UWXH

APPA Corporate Presentation
http://www.appharma.com/PDFs/A.P.%20Pharma%20Corporate%20Presentation%20-%20July%202012.pdf

http://www.forbes.com/profile/kevin-tang/

http://www.ardeabio.com/about/board-of-directors.htm

http://phx.corporate-ir.net/Tearsheet.ashx?c=115565


Strong Board of Directors..Robert Rosen
http://phx.corporate-ir.net/phoenix.zhtml?c=115565&p=irol-newsArticle&ID=1720239&highlight=

Dec. 13th..A.P. Pharma names Mark Gelder as senior VP & CMO
http://www.appharma.com/PDFs/12-13-12-Gelder-Appointment.pdf

About APF530
A.P. Pharma's lead product candidate, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company's proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV, whereas currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

Patient Satisfaction With Control of Emesis Following Chemotherapy: Comparison of APF530, a Subcutaneous Extended-Release Formulation of Granisetron, Versus Intravenous Palonosetron

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDcxNzcxfENoaWxkSUQ9NTAyOTM4fFR5cGU9MQ==&t=1

Strong Patent Protection
http://phx.corporate-ir.net/phoenix.zhtml?c=115565&p=irol-newsArticle&ID=1713090&highlight=



http://www.appharma.com/PDFs/10-16-12-APF530-NDA-Acceptance.pdf

Insider Trades History